IDEAYA Biosciences, Inc. Common Stock IDYA
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-12T00:58:54.237Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T21:00:02.45660073Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-12T00:58:53.904597+00:00
IDEAYA Biosciences, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 24.11 | 335.2% | 33.8% | |||
| 25Δ | 30.36 | 72.9% | 8.9% | |||
| 30Δ | 30.91 | 66.1% | 7.5% | |||
| 35Δ | 31.46 | 59.2% | 6.0% | |||
| 40Δ | 34.11 | 70.6% | 7.2% | 32.01 | 52.3% | 4.5% |
| 45Δ | 33.58 | 65.9% | 5.9% | 32.55 | 46.6% | 3.1% |
| 50Δ | 33.05 | 61.1% | 4.6% | 33.00 | 50.1% | 2.9% |
| 55Δ | 32.52 | 56.4% | 3.3% | 33.45 | 53.6% | 2.6% |
| 60Δ | 31.81 | 70.2% | 3.2% | 33.90 | 57.2% | 2.3% |
| 65Δ | 31.10 | 84.7% | 3.2% | 34.34 | 60.7% | 2.0% |
| 70Δ | 30.39 | 99.2% | 3.2% | 34.79 | 64.2% | 1.7% |
| 75Δ | 29.64 | 106.0% | 2.9% | 35.87 | 75.6% | 1.5% |
| 80Δ | 28.84 | 103.5% | 2.2% | 37.47 | 93.7% | 1.4% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 24.11
- IV
- 335.2%
- B/E move
- 33.8%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 30.36
- IV
- 72.9%
- B/E move
- 8.9%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 30.91
- IV
- 66.1%
- B/E move
- 7.5%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 31.46
- IV
- 59.2%
- B/E move
- 6.0%
40Δ
- Pseudo strike
- 34.11
- IV
- 70.6%
- B/E move
- 7.2%
- Pseudo strike
- 32.01
- IV
- 52.3%
- B/E move
- 4.5%
45Δ
- Pseudo strike
- 33.58
- IV
- 65.9%
- B/E move
- 5.9%
- Pseudo strike
- 32.55
- IV
- 46.6%
- B/E move
- 3.1%
50Δ
- Pseudo strike
- 33.05
- IV
- 61.1%
- B/E move
- 4.6%
- Pseudo strike
- 33.00
- IV
- 50.1%
- B/E move
- 2.9%
55Δ
- Pseudo strike
- 32.52
- IV
- 56.4%
- B/E move
- 3.3%
- Pseudo strike
- 33.45
- IV
- 53.6%
- B/E move
- 2.6%
60Δ
- Pseudo strike
- 31.81
- IV
- 70.2%
- B/E move
- 3.2%
- Pseudo strike
- 33.90
- IV
- 57.2%
- B/E move
- 2.3%
65Δ
- Pseudo strike
- 31.10
- IV
- 84.7%
- B/E move
- 3.2%
- Pseudo strike
- 34.34
- IV
- 60.7%
- B/E move
- 2.0%
70Δ
- Pseudo strike
- 30.39
- IV
- 99.2%
- B/E move
- 3.2%
- Pseudo strike
- 34.79
- IV
- 64.2%
- B/E move
- 1.7%
75Δ
- Pseudo strike
- 29.64
- IV
- 106.0%
- B/E move
- 2.9%
- Pseudo strike
- 35.87
- IV
- 75.6%
- B/E move
- 1.5%
80Δ
- Pseudo strike
- 28.84
- IV
- 103.5%
- B/E move
- 2.2%
- Pseudo strike
- 37.47
- IV
- 93.7%
- B/E move
- 1.4%
Options history
Table
| Date | IV (%) |
|---|---|
| 71.62% | |
| 100.01% | |
| 49.90% | |
| 56.81% | |
| 50.05% | |
| 55.13% | |
| 52.49% | |
| 52.14% | |
| 55.87% | |
| 57.52% | |
| 54.98% | |
| 51.90% | |
| 54.24% | |
| 50.93% | |
| 61.96% | |
| 82.96% | |
| 130.62% | |
| 54.46% | |
| 53.33% | |
| 51.13% | |
| 53.82% | |
| 54.12% | |
| 53.76% | |
| 54.63% | |
| 54.01% | |
| 55.13% | |
| 57.14% | |
| 56.63% | |
| 63.50% | |
| 57.51% | |
| 58.87% | |
| 60.50% | |
| 54.21% | |
| 60.70% | |
| 67.03% | |
| 126.73% | |
| 87.78% | |
| 62.06% | |
| 62.11% | |
| 60.28% | |
| 58.56% | |
| 60.65% | |
| 57.07% | |
| 63.17% | |
| 64.00% | |
| 60.00% | |
| 60.22% | |
| 57.77% |
Biotechnology
IFRX
InflaRx NV, a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company is…
More →IGC
Description unavailable
More →IMCR
Immunocore Holdings Limited, an advanced stage biotechnology company, develops immunotherapies for the treatment of cancer, infectious and autoimmune diseases. The company is…
More →IMMX
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, is dedicated to the development of various tissue-specific therapies in oncology and inflammation in the United…
More →IMNM
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapies for oncology and infectious diseases. The company is headquartered in Exton, Pennsylvania.
More →IMRX
Immuneering Corp (IMRX) is a cutting-edge biotechnology firm dedicated to advancing targeted therapeutics for cancer and other critical illnesses through its proprietary drug…
More →